(19)
(11) EP 3 496 724 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.11.2021 Bulletin 2021/46

(45) Mention of the grant of the patent:
06.10.2021 Bulletin 2021/40

(21) Application number: 17840401.8

(22) Date of filing: 14.08.2017
(51) International Patent Classification (IPC): 
C07D 471/14(2006.01)
A61P 35/00(2006.01)
 A61K 31/519(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; C07D 471/14
(86) International application number:
PCT/US2017/046715
(87) International publication number:
WO 2018/031987 (15.02.2018 Gazette 2018/07)

(54)

PROTEIN KINASE REGULATORS

PROTEINKINASEREGULATOREN

RÉGULATEURS DE PROTÉINE KINASES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 12.08.2016 US 201662374399 P

(43) Date of publication of application:
19.06.2019 Bulletin 2019/25

(73) Proprietors:
  • Madera Therapeutics, LLC
    Cary, NC 27513 (US)
  • Iwanowicz, Edwin, J.
    Cary, North Carolina 27513 (US)

(72) Inventor:
  • IWANOWICZ, Edwin, J.
    Cary, North Carolina 27513 (US)

(74) Representative: Winter, Brandl - Partnerschaft mbB 
Alois-Steinecker-Straße 22
85354 Freising
85354 Freising (DE)


(56) References cited: : 
EP-A1- 3 315 498
WO-A1-2016/123571
US-A1- 2008 206 312
 WO-A1-2016/123183
CN-A- 104 860 948
US-A1- 2012 115 875
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).